1921
Volume 98, Issue 3
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

Poor-quality medicines are a threat to public health in many low- and middle-income countries, and prospective surveys are needed to inform corrective actions. Therefore, we conducted a cross-sectional survey on a sample of products used for children and available in the private market in Kinshasa, Democratic Republic Congo: amoxicillin (AX) and artemether/lumefantrine (AL), powders for suspension, and paracetamol (PC) tablets 500 mg. Overall, 417 products were covertly purchased from 61 wholesalers. To obtain a representative sample, the products were weighted on their market shares and a subset of 239 samples was randomly extracted to undergo in-depth visual inspection locally, and they were chemically assessed at two accredited laboratories in Belgium. Samples were defined of “poor-quality” if they failed to comply with at least one specification of the International Pharmacopoeia (for AL) or United States Pharmacopoeia 37 (for AX and PC). Results are reported according to the Medicine Quality Assessment Reporting Guideline. The visual inspection detected nonconformities in the aspects of antimalarial powders for suspension, and poor-quality labels across all medicine types. According to chemical analysis, 27.2% samples were of poor quality and 59.5% of AL samples were underdosed in artemether. Poor quality was more frequent for locally manufactured antimalarials (83.3%, = 0.021; 86.4%, = 0.022) and PC (4.8%, = 0.000). The poor quality of the surveyed products may decrease the treatment’s efficacy and favor the development of resistances to antimalarials. It is hoped that these findings may guide the corrective actions of the Democratic Republic of Congo Regulatory Authority, which was the main partner in the research.

[open-access] This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Loading

Article metrics loading...

The graphs shown below represent data from March 2017
/content/journals/10.4269/ajtmh.17-0732
2018-01-08
2019-09-17
Loading full text...

Full text loading...

/deliver/fulltext/14761645/98/3/tpmd170732.html?itemId=/content/journals/10.4269/ajtmh.17-0732&mimeType=html&fmt=ahah

References

  1. Johnston A, Holt DW, , 2014. Substandard drugs: a potential crisis for public health. Br J Clin Pharmacol 78: 218243. [Google Scholar]
  2. Hajjou M, 2015. Monitoring the quality of medicines: results from Africa, Asia, and South America. Am J Trop Med Hyg 92 (6 Suppl): 6874. [Google Scholar]
  3. Otte WM, van Diessen E, van Eijsden P, van der Maas F, Patsalos PN, Newton PN, Alvarenga IC, Braun KP, Sander JW, , 2015. Counterfeit antiepileptic drugs threaten community services in Guinea-Bissau and Nigeria. Lancet Neurol 14: 10751076. [Google Scholar]
  4. Pan H, Luo H, Chen S, Ba-Thein W, , 2016. Pharmacopoeial quality of antimicrobial drugs in southern China. Lancet Glob Health 4: e300e302. [Google Scholar]
  5. Bassat Q, Tanner M, Guerin PJ, Stricker K, Hamed K, , 2016. Combating poor-quality anti-malarial medicines: a call to action. Malar J 15: 302. [Google Scholar]
  6. Fadeyi I, Lalani M, Mailk N, Van Wyk A, Kaur H, , 2015. Quality of the antibiotics—amoxicillin and co-trimoxazole from Ghana, Nigeria, and the United Kingdom. Am J Trop Med Hyg 92 (6 Suppl): 8794. [Google Scholar]
  7. Kaur H, 2015. Quality of artemisinin-based combination formulations for malaria treatment: prevalence and risk factors for poor quality medicines in public facilities and private sector drug outlets in Enugu, Nigeria. PLoS One 10: 113. [Google Scholar]
  8. Aldhous P, , 2005. Counterfeit pharmaceuticals: murder by medicine. Nature 434: 132136. [Google Scholar]
  9. Mitka M, , 2010. Heparin contamination. JAMA 303: 2241. [Google Scholar]
  10. Pribluda VS, Evans L, 3rd Barillas E, Marmion J, Lukulay P, Chang J, , 2014. Were medicine quality and pharmaceutical management contributing factors in diminishing artemisinin efficacy in Guyana and Suriname? Malar J 13: 15. [Google Scholar]
  11. Belew S, 2015. Assessment of efficacy and quality of two albendazole brands commonly used against soil-transmitted helminth infections in school children in Jimma Town, Ethiopia. PLoS Negl Trop Dis 9: e0004057. [Google Scholar]
  12. Newton PN, Caillet C, Guerin PJ, , 2016. A link between poor quality antimalarials and malaria drug resistance? Expert Rev Anti Infect Ther 14: 531533. [Google Scholar]
  13. World Health Organization, 2011. Pharmacovigilance and Safety of Medicines. The World Medicines Situation 2011. WHO Press, World Health Organization, Geneva, Switzerland. Available at: http://apps.who.int/medicinedocs/documents/s18771en/s18771en.pdf.
  14. Newton PN, 2011. Poor quality vital anti-malarials in Africa—an urgent neglected public health priority. Malar J 10: 352. [Google Scholar]
  15. Ravinetto RM, Boelaert M, Jacobs J, Pouget C, Luyckx C, , 2012. Poor-quality medical products: time to address substandards, not only counterfeits. Trop Med Int Health 17: 14121416. [Google Scholar]
  16. Tabernero P, Fernandez MF, Green M, Guerin PJ, Newton PN, , 2014. Mind the gaps—the epidemiology of poor-quality anti-malarials in the malarious world—analysis of the WorldWide Antimalarial Resistance Network database. Malar J 13: 139. [Google Scholar]
  17. Almuzaini T, Choonara I, Sammons H, , 2013. Substandard and counterfeit medicines: a systematic review of the literature. BMJ Open 3: e002923. [Google Scholar]
  18. Tremblay M, , 2013. Medicines counterfeiting is a complex problem: a review of key challenges across the supply chain. Curr Drug Saf 8: 4355. [Google Scholar]
  19. Preston C, Valdez ML, Bond K, , 2012. Strengthening medical product regulation in low- and middle-income countries. PLoS Med 9: e1001327. [Google Scholar]
  20. Mackintosh M, Chaudhuri S, Mujinja PG, , 2011. Can NGOs regulate medicines markets? Social enterprise in wholesaling, and access to essential medicines. Global Health 7: 4. [Google Scholar]
  21. Nebot Giralt A, Schiavetti B, Meessen B, Pouget C, Caudron C, Marchal B, Massat P, Thys R, Ravinetto R, , 2017. Quality assurance of medicines supplied to low- and middle-income countries: poor products in shiny boxes? BMJ Global Health 2: e000172. [Google Scholar]
  22. Oshikoya KA, Senbanjo IO, , 2010. Medicine turned poison for children in Nigeria. West Afr J Med 29: 278279. [Google Scholar]
  23. Alkahtani S, Sammons H, Choonara I, , 2010. Epidemics of acute renal failure in children (diethylene glycol toxicity). Arch Dis Child 95: 10621064. [Google Scholar]
  24. Renschler JP, Walters KM, Newton PN, Laxminarayan R, , 2015. Estimated under-five deaths associated with poor-quality antimalarials in sub-Saharan Africa. Am J Trop Med Hyg 92 (6 Suppl): 119126. [Google Scholar]
  25. Conway J, Bero L, Ondari C, Wasan KM, , 2013. Review of the quality of pediatric medications in developing countries. J Pharm Sci 102: 14191433. [Google Scholar]
  26. You D, Hug L, Ejdemyr S, Beise J, Idele P, , 2015. World Child Mortality 2015. UNICEF WHO World Bank United Nations. 74. Available at: https://www.unicef.org/publications/files/Child_Mortality_Report_2015_Web_9_Sept_15.pdf.
  27. Chenge MF, Van Der Vennet J, Luboya NO, Vanlerberghe V, Mapatano MA, Criel B, , 2014. Health-seeking behaviour in the city of Lubumbashi, Democratic Republic of the Congo: results from a cross-sectional household survey. BMC Health Serv Res 14: 173. [Google Scholar]
  28. Republique Democratique du Congo, Ministère de la Santé Publique, Secrétariat Général, 2010. Plan National de Développement Sanitaire PNDS 2011-2015. Mars 2010. Available at: http://www.nationalplanningcycles.org/sites/default/files/country_docs/Democratic%20Republic%20of%20Congo/pnds_2011-2015.pdf.
  29. Peyraud N, 2017. An epidemic of dystonic reactions in central Africa. Lancet Glob Heal 5: e137e138. [Google Scholar]
  30. Gaudiano MC, Di Maggio A, Cocchieri E, Antoniella E, Bertocchi P, Alimonti S, Valvo L, , 2007. Medicines informal market in Congo, Burundi and Angola: counterfeit and sub-standard antimalarials. Malar J 6: 22. [Google Scholar]
  31. Atemnkeng MA, De Cock K, Plaizier-Vercammen J, , 2007. Quality control of active ingredients in artemisinin-derivative antimalarials within Kenya and DR Congo. Trop Med Int Health 12: 6874. [Google Scholar]
  32. World Health Organization, 2007. Survey of the Quality of Antiretroviral Medicines Circulating in Selected African Countries. Geneva, Switzerland: Prequalification Programme, Quality Assurance & Safety: Medicines, Department of Medicines Policy and Standards, World Health Organization. 158. Available at: http://apps.who.int/medicinedocs/documents/s14230e/s14230e.pdf.
  33. Bate R, Jensen P, Hess K, Mooney L, Milligan J, , 2013. Substandard and falsified anti-tuberculosis drugs: a preliminary field analysis. Int J Tuberc Lung Dis 17: 308311. [Google Scholar]
  34. World Health Organization, 2011. Survey of the Quality of Selected Antimalarial Medicines Circulating in Six Countries of Sub-Saharan Africa. Geneva, Switzerland: WHO Press, World Health Organization. Available at: http://www.who.int/medicines/publications/WHO_QAMSA_report.pdf.
  35. Central Intelligence Agency, 2017. The World Factbook 2015. The Democratic Republic of Congo. Washington, DC: Central Intelligence Agency. Available at: https://www.cia.gov/library/publications/the-world-factbook/geos/cg.html.
  36. Newton PN, 2009. Guidelines for field surveys of the quality of medicines: a proposal. PLoS Med 6: e52. [Google Scholar]
  37. Bofenda Totingo P, , 2013. Compilation des Textes Législatifs et Règlementaires du Secteur Pharmaceutique en RDC, 1ère edition.
  38. Les Codes Larcier de la Republique Democratique du Congo, Vol. 2. Ordonnance-loi n°72/046 du 14/9/1972 sur l’exercice de la pharmacie. Larcier, Afrique Editions, 2002.
  39. Les Codes Larcier de la Republique Democratique du Congo, ord.72/046. Ordonnance n°72/359 du 14/9/1972 portant mesures d’exécution de l’ordonnance loi n°72/046 du 14/9/1972. Larcier, Afrique Editions, 2002.
  40. World Health Organization, 2009. Stability Testing of Active Pharmaceutical Ingredients and Finished Pharmaceutical Products. WHO Technical Report Series, No. 953, Annex 2. Geneva, Switzerland: World Health Organization.
  41. World Health Organization, 2016. The International Pharmacopoeia, 6th edition. Geneva, Switzerland: WHO Department of Essential Medicines and Health Products. World Health Organization. Available at: http://apps.who.int/phint/en/p/about/.
  42. Be Aware Tool for Visual Inspection of Medicines. Quality Assurance and Safety of Medicines (QSM) and Essential Medicine Department (EDM). Geneva, Switzerland: World Health Organization. Available at: http://www.whpa.org/toolkit_beaware_inspection.pdf.
  43. World Health Organization, 2002. Guideline on Packaging for Pharmaceutical Products. WHO Technical Report Series, No. 902, Annex 9. Geneva, Switzerland: World Health Organization. Available at: http://apps.who.int/medicinedocs/documents/s19638en/s19638en.pdf.
  44. United States Pharmacopoeial Convention (USP), 2013. The Pharmacopeial Convention and National Formulary. USP37-NF32. Rockville, Maryland: The United States Pharmacopoeial Convention. Available at: http://store.usp.org/OA_HTML/ibeCCtpItmDspRte.jsp?item=1151090&section=10071&beginIndex=0&sitex=10020:22372:US.
  45. Hall Z, Allan EL, van Schalkwyk DA, van Wyk A, Kaur H, , 2016. Degradation of artemisinin-based combination therapies under tropical conditions. Am J Trop Med Hyg 94: 9931001. [Google Scholar]
  46. Tabernero P, Parker M, Ravinetto R, Phanouvong S, Yeung S, Kitutu FE, Cheah PY, Mayxay M, Guerin PJ, Newton PN, , 2016. Ethical challenges in designing and conducting medicine quality surveys. Trop Med Int Health 21: 799806. [Google Scholar]
  47. RDC, 2012. Ministère de la Santé Publique, Direction de la Pharmacie et du Médicament. Répertoire des Produits Pharmaceutiques enregistrés et autorisés par la DPM en RDC. 1ère edition.
  48. Tivura M, 2016. Quality of Artemisinin-based combination therapy for malaria found in Ghanaian markets and public health implications of their use. BMC Pharmacol Toxicol 17: 48. [Google Scholar]
  49. Onwujekwe O, Kaur H, Dike N, Shu E, Uzochukwu B, Hanson K, Okoye V, Okonkowo P, , 2009. Quality of anti-malarial drugs provided by public and private healthcare providers in south-east Nigeria. Malar J 8: 22. [Google Scholar]
  50. Kaur H, Goodman C, Thompson E, Thompson K-A, Masanja I, Kachur SP, Abdulla S, , 2008. A nationwide survey of the quality of antimalarials in retail outlets in Tanzania. PLoS One 3: e3403. [Google Scholar]
  51. Chikowe I, Osei-Safo D, Harrison JJ, Konadu DY, Addae-Mensah I, , 2015. Post-marketing surveillance of anti-malarial medicines used in Malawi. Malar J 14: 127. [Google Scholar]
  52. Tabernero P, 2015. A repeat random survey of the prevalence of falsified and substandard antimalarials in the Lao PDR: a change for the better. Am J Trop Med Hyg 92 (6 Suppl): 95104. [Google Scholar]
  53. Hetzel MW, Page-Sharp M, Bala N, Pulford J, Betuela I, Davis TME, Kavu EK, , 2014. Quality of antimalarial drugs and antibiotics in Papua New Guinea: a survey of the health facility supply chain. PLoS One 9: e96810. [Google Scholar]
  54. World Health Organization, 2014. WHO Good Manufacturing Practices for Pharmaceutical Products: Main Principles. WHO Technical Report Series, No. 986, Annex 2. World Health Organization, Geneva, Switzerland. Available at: http://www.who.int/medicines/areas/quality_safety/quality_assurance/TRS986annex2.pdf.
  55. World Health Organization, 2010. WHO Good Distribution Practices for Pharmaceutical Products. WHO Technical Report Series, No. 957, Annex 5. Geneva, Switzerland: World Health Organization. Available at: www.who.int/medicines/areas/quality_safety/quality_assurance/GoodDistributionPracticesTRS957Annex5.pdf.
  56. Elliott I, Mayxay M, Yeuichaixong S, Lee SJ, Newton PN, , 2014. The practice and clinical implications of tablet splitting in international health. Trop Med Int Health 19: 754760. [Google Scholar]
  57. De Spiegeleer B, Van Hoorebeke L, De Spiegeleer A, Castelein P, Van Bortel L, , 2009. The paradox of scored tablets: a cost-saving risk. Pharmazie 64: 550552. [Google Scholar]
  58. World Health Organization, 2016. Guidelines on the Conduct of Surveys of the Quality of Medicines. WHO Technical Report Series, No. 996, Annex 7. Geneva, Switzerland: World Health Organization. Available at: http://apps.who.int/medicinedocs/en/d/Js22404en/.
  59. United States Pharmacopeia. Drug Quality and Information Program, 2007. Ensuring the Quality of Medicines in Resource-Limited Countries: An Operational Guide. Rockville, Maryland: The United States Pharmacopeial Convention. Available at: http://apps.who.int/medicinedocs/documents/s18424en/s18424en.pdf.
  60. WHO, 2017. Who Member State Mechanism On Substandard/Spurious/Falselylabelled/Falsified/Counterfeit (SSFFC) Medical Products Working Definitions, Appendix 3. Geneva, Switzerland: World Health Organization. Available at: http://www.who.int/medicines/regulation/ssffc/A70_23-en1.pdf?ua=1.
  61. Newton PN, Amin AA, Bird C, Passmore P, Dukes G, Tomson G, Simons B, Bate R, Guerin PJ, White NJ, , 2011. The primacy of public health considerations in defining poor quality medicines. PLoS Med 8: e1001139. [Google Scholar]
  62. Buckley GJ, Gostin LO, Products CM, , 2013. Countering the Problem of Falsified and Substandard Drugs. Institute of Medicine, 1314. Washington, DC: The National Academies Press. Available at: https://www.nap.edu/catalog/18272/countering-the-problem-of-falsified-and-substandard-drugs.
  63. ’t Hoen E, Pascual F, , 2015. Viewpoint: counterfeit medicines and substandard medicines: different problems requiring different solutions. J Pub Health Policy 36: 384389. [Google Scholar]
  64. WHO, 2017. WHO Draft Guidance on Testing “Suspect falsified medicine.” Geneva, Switzerland: World Health Organization. Available at: http://www.who.int/medicines/areas/quality_safety/quality_assurance/Post-Meeting_SFFC_Testing_DraftGuidance_QAS15-634.pdf.
  65. Pourkavoos N, , 2012. Unique risks, benefits, and challenges of developing drug-drug combination products in a pharmaceutical industrial setting. Comb Prod Ther 2: 2. [Google Scholar]
  66. Amin NC, Fabre H, Blanchin M-D, Montels J, Aké M, , 2013. Determination of artemether and lumefantrine in anti-malarial fixed-dose combination tablets by microemulsion electrokinetic chromatography with short-end injection procedure. Malar J 12: 202. [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.17-0732
Loading
/content/journals/10.4269/ajtmh.17-0732
Loading

Data & Media loading...

  • Received : 20 Sep 2017
  • Accepted : 24 Nov 2017
  • Published online : 08 Jan 2018

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error